What does PHARMACURA do?

PHARMACURA is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 19 December 2014, 1 establishment.

What is the address of PHARMACURA?

The registered office of PHARMACURA is located at Marktplein 10, 1740 Ternat.

Is PHARMACURA still active?

Yes. According to the CBE (30 October 2026) PHARMACURA is active, legal situation “Normale toestand”, started on 19 December 2014.

Is PHARMACURA registered on Peppol?

Yes, PHARMACURA is registered on the Peppol network with ID 0208:0507605156.

What is the enterprise number of PHARMACURA?

The enterprise number of PHARMACURA is BE0507605156.

When was PHARMACURA founded?

PHARMACURA was founded on 19 December 2014.

Who are the directors of PHARMACURA?

According to the 2025 annual accounts, the directors of PHARMACURA are: Paul Asselman.

Is PHARMACURA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 December 2014; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMACURA make in 2025?

PHARMACURA posted a profit after taxes of € 155,159 in financial year 2025.

What is the revenue of PHARMACURA?

As a small company, PHARMACURA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 240,828.

PHARMACURA (Private Limited) - Ternat - BE0507605156

Dossier PHARMACURA, printed on 30 October 2026 from databakkes.be/en/0507605156/pharmacura. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 16 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMACURA from Ternat, company number BE0507605156, closed financial year 2025 with a result of € 155,159 after tax. For that financial year PHARMACURA recorded a gross margin of € 240,828 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 158,019 to € 155,159. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Growing

€ 1.1 million

▲ 17% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 155,159

▼ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 139,011

▼ 18% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1 million.

People and assets in 2025

Vehicles and equipment

€ 576

▼ 31% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 675,346

▼ 16% vs 2024

€ 131,216 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 14,051

▼ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 30,221

▼ 14% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 246,948 Gross margin 2022: € 246,948 First fiscal year in the series	€ 241,913 Gross margin 2023: € 241,913 ▼ 2% vs 2022 (€ 246,948) Unfavourable step	€ 243,462 Gross margin 2024: € 243,462 ▲ 1% vs 2023 (€ 241,913) Favourable step	€ 240,828 Gross margin 2025: € 240,828 ▼ 1% vs 2024 (€ 243,462) Unfavourable step	▼ 1%
Profit after taxes	€ 161,651 Profit after taxes 2022: € 161,651 First fiscal year in the series	€ 157,393 Profit after taxes 2023: € 157,393 ▼ 3% vs 2022 (€ 161,651) Unfavourable step	€ 158,019 Profit after taxes 2024: € 158,019 Unchanged (€ 157,393) Favourable step	€ 155,159 Profit after taxes 2025: € 155,159 ▼ 2% vs 2024 (€ 158,019) Unfavourable step	▼ 2%
Equity	€ 833,832 Equity 2022: € 833,832 First fiscal year in the series	€ 872,481 Equity 2023: € 872,481 ▲ 5% vs 2022 (€ 833,832) Favourable step	€ 898,445 Equity 2024: € 898,445 ▲ 3% vs 2023 (€ 872,481) Favourable step	€ 1,053,604 Equity 2025: € 1,053,604 ▲ 17% vs 2024 (€ 898,445) Favourable step	▲ 17%
Total debts	€ 1,463,862 Total debts 2022: € 1,463,862 First fiscal year in the series	€ 1,440,837 Total debts 2023: € 1,440,837 ▼ 2% vs 2022 (€ 1,463,862) Favourable step	€ 1,430,085 Total debts 2024: € 1,430,085 ▼ 1% vs 2023 (€ 1,440,837) Favourable step	€ 1,244,260 Total debts 2025: € 1,244,260 ▼ 13% vs 2024 (€ 1,430,085) Favourable step	▼ 13%
Cash	€ 138,634 Cash 2022: € 138,634 First fiscal year in the series	€ 153,948 Cash 2023: € 153,948 ▲ 11% vs 2022 (€ 138,634) Favourable step	€ 169,325 Cash 2024: € 169,325 ▲ 10% vs 2023 (€ 153,948) Favourable step	€ 139,011 Cash 2025: € 139,011 ▼ 18% vs 2024 (€ 169,325) Unfavourable step	▼ 18%
Retained profit	€ 815,232 Retained profit 2022: € 815,232 First fiscal year in the series	€ 853,881 Retained profit 2023: € 853,881 ▲ 5% vs 2022 (€ 815,232) Favourable step	€ 879,845 Retained profit 2024: € 879,845 ▲ 3% vs 2023 (€ 853,881) Favourable step	€ 1,035,004 Retained profit 2025: € 1,035,004 ▲ 18% vs 2024 (€ 879,845) Favourable step	▲ 18%
Dividend	€ 97,835 Dividend 2022: € 97,835 First fiscal year in the series	€ 118,745 Dividend 2023: € 118,745 ▲ 21% vs 2022 (€ 97,835) Unchanged	€ 132,055 Dividend 2024: € 132,055 ▲ 11% vs 2023 (€ 118,745) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 132,055) Unchanged	▼ 100%
Bank debt	€ 1,058,702 Bank debt 2022: € 1,058,702 First fiscal year in the series	€ 932,609 Bank debt 2023: € 932,609 ▼ 12% vs 2022 (€ 1,058,702) Favourable step	€ 804,832 Bank debt 2024: € 804,832 ▼ 14% vs 2023 (€ 932,609) Favourable step	€ 675,346 Bank debt 2025: € 675,346 ▼ 16% vs 2024 (€ 804,832) Favourable step	▼ 16%
Balance sheet total	€ 2,297,694 Balance sheet total 2022: € 2,297,694 First fiscal year in the series	€ 2,313,318 Balance sheet total 2023: € 2,313,318 ▲ 1% vs 2022 (€ 2,297,694) Unchanged	€ 2,328,530 Balance sheet total 2024: € 2,328,530 ▲ 1% vs 2023 (€ 2,313,318) Unchanged	€ 2,297,863 Balance sheet total 2025: € 2,297,863 ▼ 1% vs 2024 (€ 2,328,530) Unchanged	▼ 1%

Key figures of PHARMACURA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMACURA?

What happened at PHARMACURA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: profit of € 155,159 (▼ 2% vs 2024). Source: NBB ↗
Dec 19, 2014 New establishment in Ternat. KBO
2014 Paul Asselman became a director. NBB
Dec 19, 2014 Start of the company according to the CBE. KBO

In short

From € 161,651 profit in 2022 to € 155,159 profit in 2025.

Paid € 271,868 in corporate taxes since 2022.

Best year ever: 2022, with € 161,651 profit.

Paid out € 348,635 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Paul Asselman

PHARMACURA

Farmagora 99.8%

Behind PHARMACURA is Paul Asselman. It owns 99.8% of Farmagora itself.

Directors

According to the 2025 annual accounts

Paul Asselman

Bestuurder

since 2014

Establishments

Establishment units

Physical locations of this company

Registered office

Marktplein 10

1740 Ternat

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

FARMAGORA same network

€ 299,877 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0507.605.156

VAT number

BE 0507.605.156

Registered office

Marktplein 10, 1740 Ternat

Names & denominations

PHARMACURA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

19 December 2014

Peppol

Active · Active since 24 Nov 2023

Contact

[email protected]

Activities · NACE

Activiteiten van holdings

Holdings

Detailhandel in farmaceutische producten

Vervaardiging van geneesmiddelen

Vervaardiging van farmaceutische grondstoffen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMACURA

Warning lights

Financials

What happened to PHARMACURA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions